Navigation Links
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Date:10/22/2008

assumptions underlying our revised 2008 financial guidance (including key assumptions regarding, among other things, the impact of generic pantoprazole tablets on sales of Protonix, achievement of cost reductions relating to Project Impact, the timing and impact of potential generic competition for Zosyn and Effexor XR, and continued growth in sales of certain of our principal products, including Prevnar, Enbrel and our Nutrition products) prove incorrect, our actual results could differ materially from our guidance. In addition, the statements in this press release and on the related conference call regarding development and regulatory timelines for our pipeline products are subject to risks and uncertainties related to both the timing and success of regulatory submissions and review and decisions by regulatory authorities, including the possibility that regulatory authorities will not agree with our assessments of clinical data or the sufficiency of regulatory submissions, will require additional clinical trials or other data, will take longer to review our submissions than we expect, or will determine not to approve our applications. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liab
'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
2. Wyeth Announces Increase in Common Stock Dividend
3. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
4. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
5. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
8. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
9. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
10. Wyeth Declares Common and Preferred Stock Dividends
11. Wyeth Pharmaceuticals Announces Organizational Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)...  Together with its customers, Elekta raised EUR 30,575 ... Barcelona . The funds will be donated ... to improve cancer care, specifically radiation oncology care, around ... patient should be denied potentially life-saving treatment simply because ... hospitals and clinics around the world to take care ...
(Date:4/25/2015)... Join us for a webinar at ... Residence Times using the Transcreener® ADP Assay , ... is increasingly being incorporated into lead development efforts because ... efficacy, increased therapeutic window and reduced side effects. ... methods such surface plasmon resonance, conjugation of drugs can ...
(Date:4/24/2015)... and Tempe, AZ (PRWEB) April 24, 2015 ... and Arizona State University (ASU) have entered into an ... projects. , A memorandum of agreement signed by the ... distance learning, student success and other services particularly, though ... , “We have complementary strengths and a similar ...
(Date:4/24/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... National Restaurant Association’s NRA Show 2015, in Chicago, ... the company will be available to share information ...
Breaking Biology Technology:Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2
... - First publication on utility of PRDT,s prion reduction technology to, ... ... Octaplas(R), - Octapharma ... removal capacity, technical performance and product quality., MONTREAL, ...
... Printed electronics holds possibilities for applications including printed organic solar ... ... flexible displays, ST. LOUIS, June 10 Sigma-Aldrich (Nasdaq:,SIAL) announced ... leading innovator of technology for printed,electronics, to distribute its organic semiconductors ...
... N.J., June 9 Davie Floyd, Director ... Peer Group, an Informed Medical,Communications company, were ... Trainers 37th Annual Conference in Orlando, FL. ... influential dialogue, Floyd and Bresette,presented the topic ...
Cached Biology Technology:ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 2ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 3ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 4ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 5ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China 6Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials 2Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials 3Experts From The Peer Group Provide Training on Dialogue-Based Influence at the SPBT Annual Conference 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... reverse the symptoms of a rare form of muscular ... medical geneticists at Duke University Medical Center. Infants born ... die before they reach the age of two. The ... to muscles may have application in treating other muscular ...
... a new bacteria that is a natural cleanser for ... world, is an inexpensive and highly effective solution to ... be a master engineer,?said Ron Sims, biological and irrigation ... have put these carcinogens in our environment, and nature ...
... the flow of water molecules through the brain can help ... if a patient's tumor will shrink, a new study shows. ... developed the assessment, which they call a functional diffusion map. ... diffusion, or movement, of water through the brain and mapped ...
Cached Biology News:Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 2Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 3Solution to Pollution: New Bacteria Eats Toxic Waste 2Solution to Pollution: New Bacteria Eats Toxic Waste 3New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 2New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 3
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Biology Products: